Eléments de l'association
|
List of bibliographic references
Number of relevant bibliographic references: 4.Ident. | Authors (with country if any) | Title |
---|---|---|
002355 | P. Emery [Royaume-Uni] ; J E Gottenberg [France] ; A. Rubbert-Roth [Allemagne] ; P. Sarzi-Puttini [Italie] ; D. Choquette [Canada] ; V M Martínez Taboada [Espagne] ; L. Barile-Fabris [Mexique] ; R J Moots [Royaume-Uni] ; A. Ostor [Royaume-Uni] ; A. Andrianakos [Grèce] ; E. Gemmen [États-Unis] ; C. Mpofu [Suisse] ; C. Chung [États-Unis] ; L Hinsch Gylvin [Suisse] ; A. Finckh [Suisse] | Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study |
002E60 | E. Keystone [Canada] ; S. B. Cohen [États-Unis] ; P. Emery [Royaume-Uni] ; J. M. Kremer [États-Unis] ; M. Dougados [France] ; J. E. Loveless ; C. Chung [États-Unis] ; P. Wong [États-Unis] ; P. B. Lehane [Royaume-Uni] ; H. Tyrrell [Royaume-Uni] | FRI0183 Sustained inhibition of structural damage in patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor inhibitors prior to rituximab treatment: 5-year data from the reflex study |
003114 | J.-E. Gottenberg [France] ; C. Mpofu [Suisse] ; W. Bensen [Canada] ; A. Rubbert-Roth [Allemagne] ; F. Irazoque [Mexique] ; V. Martínez Taboada [Espagne] ; C. Chung [États-Unis] ; L. Hinsch-Gylvin [Suisse] ; C. Ferri [Italie] ; P. Emery [Royaume-Uni] | AB0541 Factors associated with selection of rituximab vs alternative TNF inhibitor (TNFI) following TNFI failure in patients with rheumatoid arthritis: Sub-analysis of switch-RA, a global, comparative effectiveness observational study |
003129 | E. Keystone [Canada] ; S. B. Cohen [États-Unis] ; P. Emery [Royaume-Uni] ; J. M. Kremer [États-Unis] ; M. Dougados [France] ; J. E. Loveless ; C. Chung [États-Unis] ; P. Wong [États-Unis] ; P. B. Lehane [Royaume-Uni] ; H. Tyrrell [Royaume-Uni] | AB0526 Sustained efficacy responses and a consistent safety profile with rituximab repeat treatment over 5 years in patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor inhibitors in the reflex study |
This area was generated with Dilib version V0.6.34. |